New inhaled combo aims to fight stubborn lung infections in cystic fibrosis
NCT ID NCT06016088
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an inhaled drug called RSP-1502, which combines the antibiotic tobramycin with a substance called CaEDTA, in 71 people with cystic fibrosis who have chronic Pseudomonas lung infections. The goal was to check safety and find the right dose. Participants received either RSP-1502 or a standard tobramycin inhaler to compare effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RSP-1502 (tobramycin plus CaEDTA) inhaled via nebulizer
- What this could lead to
- If it works, this could offer a new inhaled treatment to better control chronic lung infections in cystic fibrosis, potentially reducing hospital stays.
- What could go wrong
- This is an early-phase safety and dosing study with only 71 participants, so it may not show clear benefit. Side effects or lack of effectiveness could limit its use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Augusta University
Augusta, Georgia, 30912, United States
-
Center for Cystic Fibrosis at Keck Medical Center of USC
Los Angeles, California, 90033, United States
-
Columbia University Cystic Fibrosis Program
New York, New York, 10027, United States
-
Dell Children's Medical Center of Central Texas
Austin, Texas, 78723, United States
-
Lung Institute of Western Australia
Nedlands, Western Australia, Australia
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
Queensland Children's Hospital
Brisbane, Queensland, Australia
-
Rainbow Babies and Children's Hospital / University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
Royal Adelaide Hospital
Adelaide, South Australia, Australia
-
Royal Prince Albert Hospital
Camperdown, New South Wales, Australia
-
Stanford University Medical Center
Palo Alto, California, 94305, United States
-
The Alfred Hospital
Melbourne, Victoria, Australia
-
The Cystic Fibrosis Institute
Northfield, Illinois, 60093, United States
-
The Kids Research Institute Australia, Perth Children's Hospital
Perth, Western Australia, Australia
-
The Minnesota Cystic Fibrosis Center
Minneapolis, Minnesota, 55403, United States
-
The Prince Charles Hospital
Brisbane, Queensland, Australia
-
The Royal Children's Hospital
Parkville, Victoria, Australia
-
Tucson Cystic Fibrosis Center
Tucson, Arizona, 85750, United States
-
Tulane University
New Orleans, Louisiana, 70118, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Washington University School of Medicine
St Louis, Missouri, 63130, United States
-
Westmead Hospital
Westmead, New South Wales, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibiotic combo shows promise against superbug infections
- New study tests best antibiotic for superbug infections
- Scientists hunt superbug in water and people to stop its spread
- Gut germs may worsen illness in ICU patients
- Virus cocktail inhaled to fight Drug-Resistant lung infection
- Scientists mine patient blood for new weapons against superbug